KQ-2003 CAR-T cells for POEMS syndrome that has returned or not responded to treatment
Part of Blood & lymphatic, Brain & nervous system, Genetic & congenital, Immune system & allergy clinical trials.
This trial tests a type of immunotherapy called CAR-T cells (genetically engineered immune cells) to treat POEMS syndrome that has come back or hasn't gotten better with standard treatments. It aims to see if this treatment can help reduce symptoms and control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have POEMS syndrome that has returned or has not responded to treatment.
- You are able to walk and take care of yourself (ECOG score of 0, 1, or 2).
- Your VEGF level is 1200 nanograms per liter or higher.
- You have some nerve symptoms that affect your daily life (ONLS score of 1 or higher).
- You have not had certain prior treatments like BCMA-CD19 dual-target CAR-T cells or a stem cell transplant in the last 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, BCMA/CD3 bispecific antibody, for people with POEMS syndrome. The drug helps the immune system attack abnormal plasma cells that cause the disease. It may offer a new treatment option for those who haven't had prior anti-plasma cell therapy.
This trial tests a combination of three drugs (carfilzomib, cyclophosphamide, and dexamethasone) for people newly diagnosed with POEMS syndrome. It aims to see how well this treatment helps control the disease and its symptoms.
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
This trial tests a new type of treatment using your own immune cells (called CAR-T cells) that target two proteins on myeloma cells: BCMA and GPRC5D. It's for people whose myeloma has come back or stopped responding to standard treatments, and who may have few other options left.
This Phase 1/2 study tests C-CAR088, a lab-made immune therapy, in people with multiple myeloma that has come back or did not respond. It is for patients who have already had several standard treatments and whose disease is still measurable.
This trial tests a personalized immune-cell treatment (CAR-T) called C-CAR039 for adults with certain types of large B-cell lymphoma that has come back or did not respond to treatment. It may help by attaching to lymphoma cells and training your immune system to fight them.
Hear when a new POEMS Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.